Development of Preclinical Models to Understand and Treat Colorectal Cancer

Abstract

The establishment and validation of preclinical models that faithfully recapitulate the pathogenesis and treatment response of human colorectal cancer (CRC) is critical to expedient therapeutic advances in the clinical management of this disease. Integral to the application of precision medicine for patients diagnosed with metastatic CRC is the need to understand the molecular determinants of response for a given therapy. Preclinical models of CRC have proven invaluable in answering many of our basic questions relating to the molecular aberrations that drive colorectal tumor progression. This review will address the comparative merits and limitations of the broad spectrum of in vitro and in vivo models available for study of colorectal tumors and their response to experimental therapies.

Keywords

organoid - xenograft - genetically engineered mouse model

• References

• 1 Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A 2012; 109 (51) 21046-21051
• 2 Barretina J, Caponigro G, Stransky N. , et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483 (7391): 603-607
• 3 Lind GE, Danielsen SA, Ahlquist T. , et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011; 10: 85
• 4 Sur S, Pagliarini R, Bunz F. , et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106 (10) 3964-3969
• 5 Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19 (10) 940-945
• 6 Mouradov D, Sloggett C, Jorissen RN. , et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 2014; 74 (12) 3238-3247
• 7 Medico E, Russo M, Picco G. , et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015; 6: 7002
• 8 Hoffmann OI, Ilmberger C, Magosch S, Joka M, Jauch KW, Mayer B. Impact of the spheroid model complexity on drug response. J Biotechnol 2015; 205: 14-23
• 9 Lee SH, Hong JH, Park HK. , et al. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors. Cancer Lett 2015; 367 (01) 34-42
• 10 van de Wetering M, Francies HE, Francis JM. , et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161 (04) 933-945
• 11 Weeber F, van de Wetering M, Hoogstraat M. , et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A 2015; 112 (43) 13308-13311
• 12 Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R. Mouse models for colorectal cancer. Oncogene 1999; 18 (38) 5325-5333
• 13 Karim BO, Huso DL. Mouse models for colorectal cancer. Am J Cancer Res 2013; 3 (03) 240-250
• 14 Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009; 136 (03) 780-798
• 15 Johnson RL, Fleet JC. Animal models of colorectal cancer. Cancer Metastasis Rev 2013; 32 (1-2): 39-61
• 16 McIntyre RE, Buczacki SJ, Arends MJ, Adams DJ. Mouse models of colorectal cancer as preclinical models. BioEssays 2015; 37 (08) 909-920
• 17 Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5 (09) 741-754
• 18 Forbes SA, Beare D, Gunasekaran P. , et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 (Database issue): D805-D811
• 19 Garnett MJ, Edelman EJ, Heidorn SJ. , et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483 (7391): 570-575
• 20 Klijn C, Durinck S, Stawiski EW. , et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 2015; 33 (03) 306-312
• 21 Johnson JI, Decker S, Zaharevitz D. , et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84 (10) 1424-1431
• 22 Sarraf P, Mueller E, Jones D. , et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4 (09) 1046-1052
• 23 Kulke MH, Demetri GD, Sharpless NE. , et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8 (05) 395-399
• 24 Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006; 66 (07) 3351-3354 , discussion 3354
• 25 Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A 1991; 88 (20) 9345-9349
• 26 Rashidi B, Gamagami R, Sasson A. , et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res 2000; 6 (06) 2556-2561
• 27 Dangles-Marie V, Pocard M, Richon S. , et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007; 67 (01) 398-407
• 28 Julien S, Merino-Trigo A, Lacroix L. , et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012; 18 (19) 5314-5328
• 29 Ziemke EK, Dosch JS, Maust JD. , et al. Sensitivity of KRAS-mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6. Clin Cancer Res 2016; 22 (02) 405-414
• 30 Bertotti A, Migliardi G, Galimi F. , et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1 (06) 508-523
• 31 Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998; 25 (05) (Suppl. 11) 39-46
• 32 Migliardi G, Sassi F, Torti D. , et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012; 18 (09) 2515-2525
• 33 Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015; 15 (05) 311-316
• 34 Hidalgo M, Amant F, Biankin AV. , et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4 (09) 998-1013
• 35 Di Nicolantonio F, Bardelli A. Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?. Clin Cancer Res 2013; 19 (11) 2794-2796
• 36 Roper J, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci 2012; 33 (08) 449-455
• 37 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61 (05) 759-767
• 38 Smith G, Carey FA, Beattie J. , et al. Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002; 99 (14) 9433-9438
• 39 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487 (7407): 330-337
• 40 Hinoi T, Akyol A, Theisen BK. , et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67 (20) 9721-9730
• 41 Hung KE, Maricevich MA, Richard LG. , et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010; 107 (04) 1565-1570
• 42 Martin ES, Belmont PJ, Sinnamon MJ. , et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013; 19 (11) 2929-2940
• 43 Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74 (06) 957-967